The TAT-RasGAP(317-326) anti-cancer peptide can kill in a caspase-, apoptosis-, and necroptosis-independent manner

Tumor cell resistance to apoptosis, which is triggered by many anti-tumor therapies, remains a major clinical problem. Therefore, development of more efficient therapies is a priority to improve cancer prognosis. We have previously shown that a cell-permeable peptide derived from the p120 Ras GTPase...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Heulot, Mathieu, Chevalier, Nadja, Puyal, Julien, Margue, Christiane, Michel, Sébastien, Kreis, Stephanie, Kulms, Dagmar, Barras, David, Nahimana, Aimable, Widmann, Christian
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5325447/
https://ncbi.nlm.nih.gov/pubmed/27602963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11841
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars